Physician profile
Talat Ghaus
NPI 1689623472
$6,057.15
in general payments reported to CMS, 2019-2025
24 companies · $656 in 2025
The $656 reported for 2025 was more than what 80% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $365 · 2021: $547 · 2022: $2,881 · 2023: $746 · 2024: $301 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $1,889.83 | 2022 | |
| Abbvie INC. | $1,023.02 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $750.59 | 2019-2025 | Spravato |
| Allergan, INC. | $408.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.08 | 2019-2025 | Trintellix |
| Alkermes, INC. | $330.09 | 2022-2023 | Lybalvi |
| Otsuka America Pharmaceutical, INC. | $241.27 | 2019-2025 | Rexulti |
| Lundbeck LLC | $234.05 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $200.58 | 2024-2025 | Qelbree |
| Corium, LLC | $114.78 | 2022-2024 | Azstarys |
| Livanova USA, INC. | $64.83 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neuronetics, INC. | $57.68 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.01 | 2020-2023 | |
| Axsome Therapeutics, INC. | $52.07 | 2024-2025 | Auvelity |
| Shire North American Group INC | $43.16 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $37.81 | 2019 | |
| Ironshore Pharmaceuticals INC. | $36.96 | 2019 | |
| Adlon Therapeutics L.P. | $32.73 | 2021 | |
| Bausch Health US, LLC | $28.13 | 2019 | |
| Almatica Pharma LLC | $22.39 | 2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $19.92 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $15.21 | 2022 | |
| Alfasigma USA, INC. | $12.91 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talat Ghaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.